稳健医疗业务结构均衡，消费品和医疗产品各占约 50%。2008 年起， 公司从医疗产品 ODM 出口转型为健康消费品公司，电商渠道占比超 60%，直营渠道约 30%。 2015-2024 年，公司营收复合增长率 19%，规模复合增长率 14%。2025 年上半年，公司整体盈利能力提升，净利率和毛利率均处 于周期向上阶段，预计公司将进入盈利改善周期。 公司股权结构集中，李董持股 51%。2019 年后加快引入消费品管理层， 团队架构稳定。2024 年发布股权激励计划，设定 25-27 年营收增长触 发值 13%和目标值 18%。 消费者习惯转向健康、悦己、品质便捷，内容营销平台加速渗透。公司 在棉柔巾和卫生巾领域进行创新，如添加乳霜、益生菌、全棉表层等， 并细化场景应用。 2024 年渠道结构变化，抖音增速放缓，天猫和京东提速。全棉时代等 品牌在传统渠道回暖，寻求新的增长动能。传统电商平台整体提速。 Q&A 稳健医疗 20250825 摘要 请介绍一下稳健医疗的公司背景及其主要业务结构。 稳健医疗是一家以棉为核心，涵盖医疗和消费板块协同发展的医疗健康企业。 公司的产品结构主要分为两大类：医疗产品和健康生活消费品 ...

证券研究报告·公司点评报告·个护用品 稳健医疗（300888） 2025 年中报点评：双主业并驾齐驱，稳健向好 2025 年 08 月 25 日 增持（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 8,185 | 8,978 | 11,219 | 12,866 | 14,764 | | 同比（%） | (27.89) | 9.69 | 24.96 | 14.68 | 14.75 | | 归母净利润（百万元） | 580.40 | 695.38 | 1,044.52 | 1,237.42 | 1,494.17 | | 同比（%） | (64.84) | 19.81 | 50.21 | 18.47 | 20.75 | | EPS-最新摊薄（元/股） | 1.00 | 1.19 | 1.79 | 2.12 | 2.57 | | P/E（现价&最新摊薄） | 42.23 | 35.25 | 23.47 | 19.81 | 1 ...

稳健医疗 · 300888 并驾齐驱 稳健前行 2025年半年度业绩推介材料 2025 年 8 月 免责声明 19.1 21.2 26.1 26.9 Q1 Q2 营业收入 （亿元） 各季度营业收入情况 业务结构 （亿元） 医用耗材业务 消费品业务 47% 52% 其他 1% 21.1 41.8 40.6 51.6 42.7 40.3 53.0 2019H1 2020H1 2021H1 2022H1 2023H1 2024H1 2025H1 36.5% 26.7% 31.3% 本材料由稳健医疗用品股份有限公司（以下简称"公司"）准备，仅供参考和一般信息之用 。您观看本材料 就表明您已经确认并同意如下限制： 本材料中包含的信息仅供参考和一般信息之用，不得以任何方式复制 、向任何其他人披露或散发 、或在 任何其他报告或文件中引用或使用。 本材料中包含的信息为截至相应报告期日的判断，可能发生变化，公司不承担任何更新该等信息的义务。 公司或其关联人、雇员不承担任何由于对本材料或其内容的任何使用而造成的任何损失，或以其它方式产 生的与本材料相关的损失。 01 上半年财务表现 02 上半年业务回顾 上半年财务表现 两大主业 ...

证券代码：300888 证券简称：稳健医疗 稳健医疗用品股份有限公司投资者关系活动记录表 编号：2025-006 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 √业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （电话会议） | | 参与单位名称 | 交银施罗德基金、嘉实基金、信达澳亚基金等 139 位机构投资者，名单详见 | | 及人员姓名 | 附件（排名不分先后） | | 时间 | 年 月 日 2025 8 22 | | 地点 | 公司总部会议室 | | | 方修元：董事、首席财务官 | | 上市公司接待 | 吴克震：监事、医疗板块轮值 CEO | | 人员姓名 | 廖美珍：董事、全棉时代高级副总裁 | | | 陈惠选：副总经理、董事会秘书 | | | 介绍内容详见附件业绩推介材料，问答记录如下： | | 1. | 请问公司如何看待全棉时代近期恢复情况，并请分享一下消费品业务下 | | | 半年展望以及未来 1-2 年的核心增长动力。 | | | 答：首先，全棉时代第二季度实现 13%同比增长，公 ...

上 市 公 司 美容护理 2025 年 08 月 24 日 稳健医疗 (300888) —— 消费品核心品类引领增长，医疗业务二季度提速 报告原因：有业绩公布需要点评 买入（维持） 本研究报告仅通过邮件提供给 中庚基金 使用。1 投资要点： | 市场数据： | 2025 年 08 月 22 日 | | --- | --- | | 收盘价（元） | 42.09 | | 一年内最高/最低（元） | 54.80/23.31 | | 市净率 | 2.1 | | 股息率%（分红/股价） | 1.54 | | 流通 A 股市值（百万元） | 7,391 | | 上证指数/深证成指 | 3,825.76/12,166.06 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 06 月 30 日 | | --- | --- | | 每股净资产（元） | 19.79 | | 资产负债率% | 31.87 | | 总股本/流通 A 股（百万） | 582/176 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 08-22 09-22 10-22 11-22 ...

Core Insights - The company reported a significant increase in revenue and profit for the first half of 2025, with total revenue reaching 5.3 billion yuan, a year-on-year growth of 31.3%, and net profit attributable to shareholders at 490 million yuan, up 28.1% [1] - The medical and consumer segments both contributed to this growth, with revenues of 2.52 billion yuan and 2.75 billion yuan respectively, marking increases of 46.4% and 20.3% [1] Group 1: Consumer Segment Performance - The consumer brand, 全棉时代, achieved revenue of 2.75 billion yuan in the first half of 2025, reflecting a growth of 20.3% [2] - Key products such as the core dry and wet cotton soft towels saw sales increase to 810 million yuan, a growth of 19.5%, while sanitary napkins experienced a remarkable revenue increase of 67.6%, reaching 530 million yuan [2] - The brand's membership base grew to nearly 67 million, a 7.7% increase from the previous year, indicating strong customer loyalty and engagement [3] Group 2: Medical Segment Performance - The medical segment reported revenue of 2.52 billion yuan, a substantial increase of 46.4%, with organic growth excluding acquisitions contributing to a 13.2% rise [4] - Key innovations in the medical field included a 193.5% increase in revenue from surgical consumables, reaching 740 million yuan, and a 25.7% increase in high-end dressings, totaling 480 million yuan [4] - The company holds 1,109 R&D patents and 701 medical product registration certificates, establishing a strong foundation for future growth in both domestic and international markets [4] Group 3: Brand and Financial Strategy - The company announced a cash dividend distribution plan of 260 million yuan, representing 53.26% of net profit, reflecting a commitment to shareholder returns [5] - The brand aims to enhance its image and market position through various promotional activities and product innovations, reinforcing its commitment to quality and consumer health [5] - The company is focused on a long-term vision of sustainable growth, emphasizing the importance of brand elevation and maintaining industry leadership through continuous investment in R&D and quality control [5]

汇涵科技 成立于2005年，总部位于苏州，是一家融合科技、医疗与消费属性的创新型企业，专注于生物医用 材料的研发与产业化。公司旗下有高端敷料、一次性手术器械、生物医用材料及日用消费品四大板块。公司以 临床需求为导向，通过自主核心技术推动医疗产品创新，为手术管理、创面修复及组织再生提供高效解决方 案。 汇涵科技依托 胶体银技术、水凝胶技术、细菌纤维素技术、生物3D技术及MT技术 五大核心平台，为临床医 疗提供高效、安全的解决方案。 公司产品涵盖止血类、手术密封类、防黏连类、软组织管理类等全系列产品，已取得含两个三类医疗器械在内 的 50多张医疗器械注册 。此外，公司还注册了如 细菌纤维素人工血管、细菌纤维素饮品等 新产品，推动创 新材料在临床医疗与大健康领域的应用。 细菌纤维素技术 北京和上海活动报名： 第三届全球手术机器人大会 2025医疗器械研发创新论坛 近日， 苏州汇涵医用科技发展有限公司 （以下简称"汇涵科技"）宣布完成 B轮融资 ，此次融资由江苏润淮 产业发展基金独家投资，资金将主要用于汇涵科技旗下生物医用材料板块的产能扩建、自动化升级及研发创 新。 # 关于汇涵科技 融资历程 思宇年度活动回顾： 首 ...

Core Viewpoint - The company, Kewei Medical, is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence and brand influence [2][3]. Group 1: Company Overview - Kewei Medical specializes in the research, production, sales, and service of medical devices, covering health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine [2]. - The company was listed on the A-share market in October 2021, achieving a net profit of approximately 429 million yuan that year, but experienced a decline in the following two years, with a recovery to 312 million yuan in 2024 [2][6]. Group 2: Internationalization Strategy - The management has indicated that the H-share issuance aligns with national policies supporting companies to "go global," and the Hong Kong market offers a high degree of internationalization and quality financing opportunities [3]. - The company aims to enhance its overseas business capabilities and optimize cross-border mergers and acquisitions through the establishment of the H-share platform [3]. Group 3: Recent Acquisitions - In the first half of the year, Kewei Medical completed acquisitions of Shanghai Huazhou and Ximaner, which are expected to strengthen its overseas business resources [2][4]. - Shanghai Huazhou, established in 2002, is a well-known domestic manufacturer of pressure-sensitive adhesive products, with over 60% of its revenue coming from overseas [4]. - Ximaner, founded in 1988, operates retail and wholesale medical device centers in Hong Kong, enhancing Kewei Medical's market presence [5]. Group 4: Financial Performance - In 2024, Kewei Medical reported revenues of 2.983 billion yuan, a year-on-year increase of 4.53%, and a net profit of 312 million yuan, up 22.6% [6]. - The company’s domestic revenue accounted for approximately 98.02% of total revenue, while overseas revenue was only about 59.15 million yuan, indicating that international operations are still in the development phase [6]. - The company has experienced significant fluctuations in performance since its IPO, with net profit dropping to approximately 254 million yuan in 2023 after a peak in 2021 [6]. Group 5: Recent Challenges - In the first quarter of the current year, Kewei Medical's revenue decreased by 8.59% to approximately 738 million yuan, and net profit fell by 9.68% to about 91.43 million yuan [7]. - The company’s sales expenses increased by 31.4% to approximately 973 million yuan, primarily due to the expansion of its retail network and increased marketing investments [6][7].

Investment Rating - The industry investment rating is "Positive" and maintained [7] Core Insights - The domestic retail market for textiles and apparel continues to show steady performance, with most companies achieving positive revenue growth, although profit margins vary significantly [2][4] - The manufacturing sector faces challenges due to weak retail performance and expectations, with inventory replenishment becoming difficult and tariffs further suppressing manufacturing performance [2][4] - The recovery of Nike's operations is expected to alleviate some negative pressures on the industry, potentially leading to a rebound in the manufacturing sector [2][4][30] Summary by Sections Brand Performance - The retail environment remains stable, with most companies reporting positive revenue growth, while profit margins show divergence [4][16] - Sub-sectors exhibit varied performance, with sports retail maintaining steady growth, mid-to-high-end menswear showing resilience, and mass-market brands facing pressure [4][20] Manufacturing Sector - The manufacturing sector is under pressure as downstream brands enter a phase of passive inventory accumulation, compounded by tariffs affecting short-term performance [4][17] - The sector is expected to face challenges in the short term, but improvements in Nike's operations may provide a positive outlook for the manufacturing sector [4][30] Key Company Performance - Companies such as Luolai Life and Weigao Medical are expected to perform well in Q2 2025, with Luolai's revenue projected to grow by 0%-5% and net profit by 20%-30% due to low base effects [5][29] - Weigao Medical anticipates a revenue increase of 23%-33% and a net profit growth of 25%-35% driven by strong performance in personal care and medical products [5][29] Detailed Company Forecasts - 361 Degrees expects a revenue growth of 10%-20% in Q2 2025, with strong performance in adult and children's apparel [6][20] - Crystal International is projected to achieve a revenue growth of 12%-16% in H1 2025, benefiting from a low base and improved product mix [6][20] Market Trends - The retail sales growth for clothing and textiles in June 2025 was 1.9%, with a sequential decline of 2.1 percentage points [25][29] - The overall retail environment remains weak, with significant variations across different segments, particularly in the mass-market sector [20][29]

Core Viewpoint - The company, Steady Medical, has shown strong performance in its consumer products and medical business segments, with significant growth in sales and profits, particularly during promotional events like the 618 shopping festival. Group 1: Consumer Products Performance - The consumer products segment performed well during the 618 shopping festival, with key categories such as facial towels, baby wet and dry wipes, and baby wraps ranking first in sales on platforms like Tmall and JD.com [2] - The company achieved notable sales growth in sanitary napkins and underwear, with traditional platforms like Tmall and JD.com showing good growth, while Douyin saw breakthrough growth during the event [2] - The company is confident in achieving its equity incentive goals for the year [2] Group 2: E-commerce Strategy - Online channels contribute over 60% to the overall revenue of the consumer products business, making it a primary source of profit [3] - The company covers a wide range of online platforms, including traditional e-commerce sites and interest-based platforms like Douyin and Xiaohongshu, as well as its own website and mini-programs [3] - Future strategies include focusing on strategic product development on traditional platforms and leveraging interest-based platforms for content dissemination to drive growth [3] Group 3: Adult Apparel Business Changes - The adult apparel segment has undergone changes to enhance market competitiveness, focusing on underwear and loungewear [4] - The company has strengthened its core fabric research and innovation, emphasizing comfort and health in its cotton products [4] - A high-profile endorsement from actress Zhao Liying has been utilized to boost brand awareness, with interactive marketing strategies during the 618 festival [4] Group 4: Membership Growth - As of the end of Q1 2025, the total membership across all channels exceeded 64 million, reflecting a 3.5% increase since the beginning of the year [5] - The company aims to enhance member engagement and loyalty through improved services and participation in brand activities [5] - A themed event focusing on comfort and environmental sustainability was held to engage young consumers [5] Group 5: Medical Business Development - The medical business strategy focuses on developing high-potential products like high-end dressings and surgical kits while nurturing emerging categories such as masks and disinfectants [6] - The company anticipates continued growth in high-end dressings and surgical supplies, with stable growth expected in traditional wound dressings [6] - The demand for infection prevention products is expected to normalize, providing stable revenue contributions [6] Group 6: Domestic Hospital Business Strategy - The domestic hospital business is expected to achieve good growth in 2025, focusing on traditional wound care, surgical supplies, and high-end dressings [7] - The company plans to leverage procurement opportunities to increase market share in traditional wound care [7] - Efforts are being made to promote non-standardized products and expand market opportunities in surgical supplies [7] Group 7: Financial Performance - For Q1 2025, the company reported a main revenue of 2.605 billion yuan, a year-on-year increase of 36.47%, and a net profit of 249 million yuan, also up 36.26% [8] - The company’s gross profit margin stands at 48.46%, indicating strong profitability [8] - Recent institutional ratings show 19 buy ratings and 3 hold ratings, with an average target price of 57.07 yuan [8]